Form 4: Elicio Therapeutics Director Acquires Stock Options

Yekaterina Chudnovsky, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Summary

• Yekaterina Chudnovsky, a director of Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.
• The options have an exercise price of $5.12 per share.
• The options will vest and become exercisable on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date, provided Ms. Chudnovsky continues to provide services to the company.
• The options expire on November 21, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative news.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The stock options will vest and become exercisable on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date, subject to the director's continued service.

Industry Context

This is a standard practice for companies to grant stock options to directors as part of their compensation and to align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, similar to companies like Moderna and BioNTech.
• The vesting schedule of one year is also typical, aligning with industry norms for incentivizing long-term commitment.
• The exercise price of $5.12 is specific to Elicio Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, ELTX, insider trading, equity, vesting